Increased Serum G Protein-coupled Estrogen Receptor 1 Levels and Its Diagnostic Value in Drug Naïve Patients with Major Depressive Disorder

다국어 초록 (Multilingual Abstract)

Objective: The facts that depression is more prevalent in females than in males and females are exposed to depression more commonly during certain hormonal fluctuating periods indicate the role of sex hormones in physiopathology. Estrogen acts over estrogen receptors alpha and beta and recently identified G protein-coupled estrogen receptor 1 (GPER1). The present study aimed, for the first time, to evaluate serum GPER1 levels in drug-naïve major depressive disorder (MDD) patients. Methods: The study included 56 newly diagnosed drug-naïve MDD patients aged between 18 and 50 years and 42 age- and gender-matched healthy volunteers. Medical history was obtained and physical examinations, laboratory tests, and the Hamilton Depression Rating Scale (HAM-D), Hamilton Anxiety Rating Scale (HAM-A) were performed. The serum GPER1 levels were measured. Results: The HAM-D score was significantly higher in the MDD patients than in the controls. The GPER1 level was significantly higher in the MDD patients than in the controls. A positive correlation was found with GPER1 levels and depression scores. The receiver operating characteristic analysis revealed sensitivity, specificity, positive predictive value, and negative predictive value as 82.1%, 90.5%, 92.0%, and 79.2%, respectively, for the presence of depression, when the serum GPER1 value was ≥0.16. Conclusion: This study demonstrated significantly higher serum GPER1 levels in the MDD patients than in the controls, a positive correlation was found between GPER1 levels and depression scores and serum GPER1 level was valuable in predicting the presence of depression.

참고문헌 (Reference)

1 Prossnitz ER, "physiological functions and clinical relevance of the G protein-coupled estrogen receptor GPER" 89 : 89-97, 2009

2 Joffe H, "Treatment of depression and menopauserelated symptoms with the serotonin-norepinephrine reuptake inhibitor duloxetine" 68 : 943-950, 2007

3 Mössner R, "The serotonin transporter in Alzheimer's and Parkinson's disease" (60) : 345-350, 2000

4 Payne JL, "The role of estrogen in mood disorders in women" 15 : 280-290, 2003

5 Keyes K, "The role of allelic variation in estrogen receptor genes and major depression in the Nurses Health Study" 50 : 1893-1904, 2015

6 Kessler RC, "The costs of depression" 35 : 1-14, 2012

7 Findikli E, "The biomarker potential of malondialdehyde, superoxide dismutase and catalase activity in drug naïve, first episode, non-smoker generalized anxiety disorder patients" 2016

8 Prossnitz ER, "The G-protein-coupled estrogen receptor GPER in health and disease" 7 : 715-726, 2011

9 Westberg L, "Sex steroid-related candidate genes in psychiatric disorders" 33 : 319-330, 2008

10 Solomon MB, "Sex differences in psychopathology:of gonads, adrenals and mental illness" 97 : 250-258, 2009

11 Fındıklı E, "Serum levels of G protein-coupled estrogen receptor 1(GPER1)in drug-naive patients with generalized anxiety disorder" 244 : 312-316, 2016

12 Mössner R, "Serotonin transporter function is modulated by brain-derived neurotrophic factor(BDNF)but not nerve growth factor(NGF)" 36 : 197-202, 2000

13 Studd J, "Reproductive depression" 28 (28): 42-45, 2012

14 ter Horst JP, "Relevance of stress and female sex hormones for emotion and cognition" 32 : 725-735, 2012

15 Thase ME, "Relative antidepressant efficacy of venlafaxine and SSRIs : sex-age interactions" 14 : 609-616, 2005

16 Wittmann W, "Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone" 34 : 775-785, 2009

17 Barton M, "Position paper: The membrane estrogen receptor GPER--Clues and questions" 77 : 935-942, 2012

18 Cyr M, "Modulation by estrogenreceptor directed drugs of 5-hydroxytryptamine-2A receptors in rat brain" 23 : 69-78, 2000

19 Hazell GG, "Localisation of GPR30, a novel G protein-coupled oestrogen receptor, suggests multiple functions in rodent brain and peripheral tissues" 202 : 223-236, 2009

20 Krezel W, "Increased anxiety and synaptic plasticity in estrogen receptor beta-deficient mice" 98 : 12278-12282, 2001

21 Dennis MK, "In vivo effects of a GPR30 antagonist" 5 : 421-427, 2009

22 van Amelsvoort T, "In vivo assessment of the effects of estrogen on human brain" 12 : 273-276, 2001

23 Stygar D, "Identification of wild type and variants of oestrogen receptors in polymorphonuclear and mononuclear leucocytes" 64 : 74-81, 2006

24 Anchan D, "GPR30activation decreases anxiety in the open field test but not in the elevated plus maze test in female mice" 4 : 51-59, 2014

25 McAllister CE, "GPER1stimulation alters posttranslational modification of RGSz1and induces desensitization of 5-HT1A receptor signaling in the rat hypothalamus" 100 : 228-239, 2014

26 Kastenberger I, "GPER1(GPR30)knockout mice display reduced anxiety and altered stress response in a sex and paradigm dependent manner" 66 : 628-636, 2014

27 Han G, "GPER : a novel target for non-genomic estrogen action in the cardiovascular system" 71 : 53-60, 2013

28 김미진, "G-protein Coupled Estrogen Receptor (GPER/GPR30) and Women’s Health" 대한폐경학회 21 (21): 79-81, 2015

29 Sandén C, "G proteincoupled estrogen receptor 1/G protein-coupled receptor 30localizes in the plasma membrane and traffics intracellularly on cytokeratin intermediate filaments" 79 : 400-410, 2011

30 Phan KL, "Functional neuroanatomy of emotion : a meta-analysis of emotion activation studies in PET and fMRI" 16 : 331-348, 2002

31 Camkurt MA, "Evaluation of malondialdehyde, superoxide dismutase and catalase activity and their diagnostic value in drug naïve, first episode, non-smoker major depression patients and healthy controls" 238 : 81-85, 2016

32 Yaffe K, "Estrogens, selective estrogen receptor modulators, and dementia: what is the evidence?" 949 : 215-222, 2001

33 Prossnitz ER, "Estrogen biology : new insights into GPER function and clinical opportunities" 389 : 71-83, 2014

34 Soares CN, "Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms" 64 : 473-479, 2003

35 Matsuda Y, "Effects of estrogen on acetylcholine release in frontal cortex of female rats : involvement of serotonergic neuronal systems" 937 : 58-65, 2002

36 Osterlund MK, "Effects of chronic 17beta-estradiol treatment on the serotonin 5-HT(1A)receptor mRNA and binding levels in the rat brain" 35 : 39-44, 2000

37 Fan HM, "Differential expression of microRNA in peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients" 59 : 45-52, 2014

38 Karlović D, "Diagnostic accuracy of serum brain derived neurotrophic factor concentration in antidepressant naïve patients with first major depression episode" 47 : 162-167, 2013

39 Soares CN, "Depression in peri- and postmenopausal women: prevalence, pathophysiology and pharmacological management" 30 : 677-685, 2013

40 Benmansour S, "Comparison of the effects of estradiol and progesterone on serotonergic function" 71 : 633-641, 2012

41 Howren MB, "Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis" 71 : 171-186, 2009

42 Ozcan ME, "Antioxidant enzyme activities and oxidative stress in affective disorders" 19 : 89-95, 2004

43 Kastenberger I, "Activation of the G-protein-coupled receptor GPR30 induces anxiogenic effects in mice, similar to oestradiol" 221 : 527-535, 2012

44 Hart D, "Activation of the G-protein coupled receptor 30(GPR30)has different effects on anxiety in male and female mice" 81 : 49-56, 2014

45 Revankar CM, "A transmembrane intracellular estrogen receptor mediates rapid cell signaling" 307 : 1625-1630, 2005

46 Walf AA, "A review and update of mechanisms of estrogen in the hippocampus and amygdala for anxiety and depression behavior" 31 : 1097-1111, 2006

47 Hiles SA, "A meta-analysis of differences in IL-6 and IL-10 between people with and without depression : exploring the causes of heterogeneity" 26 : 1180-1188, 2012

48 Studd JW, "A guide to the treatment of depression in women by estrogens" 14 : 637-642, 2011

49 Langer G, "A critical review of fundamental controversies in the field of GPR30 research" 75 : 603-610, 2010